177lu-rm2
Small moleculeexperimentalImaging agent
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2019 (NCT03872778)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 177-lutetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06247995 | Phase 1/Phase 2 (Phase 2) | Aug 14, 2024 | Novartis |
| NCT06379217 | Phase 1 | Jul 29, 2024 | Novartis |
| NCT05739942 | Phase 1 | Apr 1, 2024 | Novartis |
| NCT05870579 | Phase 1 | Nov 13, 2023 | Novartis |
| NCT03872778 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2019 | Advanced Accelerator Applications |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 4 | 4 | 2 | 2023 |
| Advanced Accelerator Applications | For profit | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1